Tetanus Immunoglobulin (IV)
Presentation
Single vials containing 4000IU Human Tetanus antitoxin.
Indications for Use
Tetanus Immunoglobulin (intravenous) is issued for management of clinical tetanus. A medical officer’s approval is required to issue the intravenous product.
Precautions / Contraindications
Should only be given in the following situations if the benefits outweigh the risks.
- Patients with true anaphylactic reactions to human immunoglobulin
- Individuals with isolated Ig A deficiency who have an antibody against IgA.
Aseptic meningitis syndrome (AMS): occurs infrequently with intravenous immunoglobulin treatment; occurring within several hours to 2 days following treatment.
Occasional reports of renal dysfunction and acute renal failure, mainly with sucrose containing preparations. This product does not contain sucrose. Increased risk with patients >65years of age, pre-existing renal insufficiency, diabetes mellitus, volume depleted or taking concomitant nephrotoxitic medication.
Availability
Requests to ARCBS.
Dosage and Administration
Administered by slow intravenous infusion. Commence infusion at 1ml / minute and gradually increase to a maximum of 3 to 4 mls/min if tolerated by the patient.
Monitor vital signs closely prior to and through out infusion.
Administer separately from other intravenous infusions or medications.
The product s does not contain antimicrobial preservative; it must be used immediately after opening the vial.
Refer to the current product information sheet for further information.